Fleming D, McQuillan G, Johnson R.
et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med.1997;337:1105-1111.
Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis.1998;26:541-555.
Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes
infections. N Engl J Med.1995;333:770-775.
Corey L, Langenberg AG, Ashley R.
et al. for the Chiron HSV Vaccine Study Group. Recombinant glycoprotein vaccine for the prevention of genital HSV-2
infection: 2 randomized controlled trials. JAMA.1999;282:331-340.
Langenberg AG, Burke RL, Adair SF.
et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2:
safety and immunogenicity. Ann Intern Med.1995;122:889-898.
Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med.1992;116:197-202.
Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (Immunoblot) and G-specific immunodot enzyme
assay for detecting antibodies to herpes simplex virus types 1 and 2 in human
sera. J Clin Microbiol.1988;26:662-667.
Ashley R. Laboratory techniques in the diagnosis of herpes simplex infection. Genitourin Med.1993;69:174-183.
Ashley RL, Crisostomo FM, Doss M.
et al. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein
subunit vaccine. J Infect Dis.1998;178:1-7.
Lafferty WE, Frofft S, Remington M.
et al. Diagnosis of herpes simplex virus by direct immunofluorescence and
viral isolation from samples of external genital lesions in a high prevalence
population. J Clin Microbiol.1987;25:323-326.
Langenberg A, Zbanyszek R, Dragavon J, Ashley R, Corey L. Comparison of diploid fibroblast and rabbit kidney tissue culture and
diploid and fibroblast microtiter plate system for the isolation of herpes
simplex virus. J Clin Microbiol.1988;26:1772-1774.
Bryson YJ, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners
of persons with genital herpes: a prospective couple study. J Infect Dis.1993;167:942-946.
Royce R, Sena A, Cates W, Cohen M. Sexual transmission of HIV. N Engl J Med.1997;336:1072-1078.
Peterman T, Stoneburner R, Allen J, Jaffe H, Curran J. Risk of human immunodeficiency virus transmission from heterosexual
adults with transfusion-associated infections. JAMA.1988;259:55-58.
Downs A, DeVincenzi I.for the European Study Group in Heterosexual Transmission of HIV. Probability of heterosexual transmission of HIV: relationship to the
number of unprotected sexual contacts. J Acquir Immune Defic Syndr Hum Retrovirol.1996;11:388-395.
Centers for Disease Control and Prevention. CDC 1998 Guidelines for Treatment of Sexually Transmitted Diseases. MMWR Morb Mortal Wkly Rep.1998;47:1-118.
Wald A, Zeh J, Selke S.
et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic
HSV-2 seropositive persons. N Engl J Med.2000;342:844-850.
Kaiser Family Foundation. Sexually Transmitted Diseases in America: How Many
Cases and at What Cost? Research Triangle Park, NC: American Social Health Association; 1998.
Catania J, Coates T, Stall R.
et al. Prevalence of AIDS-related risk factors and condom use in the United
Catania JA, Binson D, Dolcini MM.
et al. Risk factors for HIV and other sexually transmitted diseases and prevention
practices among US heterosexual adults: changes from 1990 to 1992. Am J Public Health.1995;85:1492-1499.
Anderson JE, Wilson RW, Barker P, Doll L, Jones TS, Holtgrave D. Prevalence of sexual and drug-related HIV risk behaviors in the US
adult population: results of the 1996 National Household Survey on Drug Abuse. J Acquir Immune Defic Syndr.1999;21:148-156.
Whitbeck JC, Peng C, Lou H.
et al. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM,
a member of the tumor necrosis factor receptor superfamily and a mediator
of HSV entry. J Virol.1997;71:6083-6093.
Montgomery RI, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member
of the TNF/NGF receptor family. Cell.1996;87:427-436.
WuDunn D, Spear PG. Initial interaction of herpes simplex virus with cells is binding to
heparan sulfate. J Virol.1989;63:52-58.
Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, Oksenhendler E. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes
in noninfected heterosexual contact of HIV-infected patients. J Clin Invest.1994;93:1293-1297.
Rowland-Jones S, Nixon D, Aldhous M.
et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected
Rowland-Jones S, Sutton J, Ariyoshi K.
et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian
women. Nat Med.1995;1:59-64.
Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases
in frequency over time. Ann Intern Med.1999;131:14-20.
Mertz GJ, Schmidt O, Jourden JL.
et al. Frequency of acquisition of first-episode genital infection with herpes
simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis.1985;12:33-39.
de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by
heterosexual partners: European Study Group on Heterosexual Transmission of
HIV. N Engl J Med.1994;331:341-346.
Yankelovich Partners Inc. Americans' 18-39 Attitudes Toward and Knowledge of
Genital Herpes. Research Triangle Park, NC: American Social Health Association; 1999.
Ashley RL, Wu L, Pickering JW, Tu MC, Schnorenberg L. Premarket evaluation of a commercial glycoprotein-G based enzyme immunoassay
for herpes simplex virus type-specific antibodies. J Clin Microbiol.1998;36:294-295.
Ashley RL, Eagleton M. Evaluation of a novel point-of-care test for antibodies to herpes simplex
virus type 2. Sex Transm Infect.1998;74:228-229.